Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

• Published in: Blood Vol. 101; no. 5; pp. 1905 - 1912
• Main Authors: Gottschalk, Stephen, Edwards, Oliver L., Sili, Uluhan, Huls, M. Helen, Goltsova, Tatiana, Davis, Alan R., Heslop, Helen E., Rooney, Cliona M.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01.03.2003; The Americain Society of Hematology
• Subjects: Adenoviruses, Human - genetics; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antigen Presentation; Antigens, Neoplasm - genetics; Antigens, Neoplasm - immunology; Antigens, Viral - genetics; Antigens, Viral - immunology; Applied cell therapy and gene therapy; Biological and medical sciences; Cytotoxicity, Immunologic; Dendritic Cells - immunology; Epitopes - immunology; Epstein-Barr Virus Infections - therapy; Epstein-Barr Virus Nuclear Antigens - genetics; Genetic Vectors - genetics; Hematologic and hematopoietic diseases; HLA-A2 Antigen - immunology; Hodgkin Disease - therapy; Hodgkin Disease - virology; Humans; Immunotherapy, Adoptive; Interferon-gamma - metabolism; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphocyte Activation; Medical sciences; T-Lymphocytes, Cytotoxic - immunology; T-Lymphocytes, Cytotoxic - metabolism; Transduction, Genetic; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Tumor Virus Infections - therapy; Vaccinia virus - genetics; Viral Matrix Proteins - genetics; Viral Matrix Proteins - immunology; Viral Matrix Proteins - toxicity; Cell therapy; Epstein Barr virus; Adoptive transfer; Antigen presenting cell; Lymphoproliferative syndrome; Immunotherapy; Established cell line; T-Lymphocyte; Complication; Malignant lymphoma; Adoptive immunization; Cytotoxic T lymphocyte; Gammaherpesvirinae; Human; Dendritic cell; Herpesviridae; Malignant hemopathy; Malignant tumor; Infection; Virus; Antigen; Treatment; Viral disease; Suppressive cell; Feasibility; Latent membrane protein 1
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2002-05-1514

The Epstein-Barr virus (EBV)–encoded LMP1 protein is expressed in EBV-positive Hodgkin disease and is a potential target for cytotoxic T-lymphocyte (CTL) therapy. However, the LMP1-specific CTL frequency is low, and so far the generation of LMP1-specific CTLs has required T-cell cloning. The toxicity of LMP1 has prevented the use of dendritic cells (DCs) for CTL stimulation, and we reasoned that an inactive, nontoxic LMP1 mutant (ΔLMP1) could be expressed in DCs and would enable the activation and expansion of polyclonal LMP1-specific CTLs. Recombinant adenoviral vectors expressing LMP1 or ΔLMP1 were tested for their ability to transduce DCs. LMP1 expression was toxic within 48 hours whereas high levels of ΔLMP1 expression were achieved with minimal toxicity. ΔLMP1-expressing DCs were able to reactivate and expand LMP1-specific CTLs from 3 healthy EBV-seropositive donors. LMP1-specific T cells were detected by interferon-γ (IFN-γ) enzyme-linked immunospot assay (ELISPOT) assays using the HLA-A2–restricted LMP1 peptide, YLQQNWWTL (YLQ). YLQ-specific T cells were undetectable (less than 0.001%) in donor peripheral blood mononuclear cells (PBMCs); however, after stimulation the frequency increased to 0.5% to 3.8%. Lysis of autologous target cells by CTLs was dependent on the level of LMP1 expression. In contrast, the frequency of YLQ-specific CTLs in EBV-specific CTLs reactivated and expanded using lymphoblastoid cell lines was low and no LMP1-specific cytotoxic activity was observed. Thus, ΔLMP1 expression in DCs is nontoxic and enables the generation of LMP1-specific CTLs for future adoptive immunotherapy protocols for patients with LMP1-positive malignancies such as EBV-positive Hodgkin disease. Targeting LMP1 in these malignancies may improve the efficacy of current adoptive immunotherapy approaches.